{"id":780944,"date":"2023-08-30T09:34:29","date_gmt":"2023-08-30T13:34:29","guid":{"rendered":"https:\/\/www.marketnewsdesk.com\/index.php\/ovid-therapeutics-to-participate-in-upcoming-september-investor-conferences\/"},"modified":"2023-08-30T09:34:29","modified_gmt":"2023-08-30T13:34:29","slug":"ovid-therapeutics-to-participate-in-upcoming-september-investor-conferences","status":"publish","type":"post","link":"https:\/\/www.marketnewsdesk.com\/index.php\/ovid-therapeutics-to-participate-in-upcoming-september-investor-conferences\/","title":{"rendered":"Ovid Therapeutics to Participate in Upcoming September Investor Conferences"},"content":{"rendered":"<div class=\"mw_release\">\n<p align=\"justify\">NEW YORK, Aug.  30, 2023  (GLOBE NEWSWIRE) &#8212; Ovid Therapeutics Inc. (NASDAQ: OVID), a biopharmaceutical company committed to developing medicines that transform the lives of people with epilepsies and seizure-related disorders, today announced that management will participate in two upcoming investor conferences.<\/p>\n<ul type=\"disc\">\n<li style=\"text-align:justify\">\n          <strong>Citi\u2019s 18<\/strong><br \/>\n          <sup><br \/>\n            <strong>th<\/strong><br \/>\n          <\/sup><br \/>\n          <strong> Annual BioPharma Conference<\/strong> \u2013 Ovid will participate on Thursday, September 7, 2023 in Boston, Massachusetts.<\/li>\n<\/ul>\n<ul type=\"disc\">\n<li style=\"text-align:justify\">\n          <strong>The H.C. Wainwright 25th Annual Global Investment Conference<\/strong> \u2013 Ovid\u2019s presentation will take place on Tuesday, September 12, 2023 at 10:30 a.m. ET in New York, New York.<\/li>\n<\/ul>\n<p align=\"left\">A live webcast of the H.C. Wainwright presentation can be accessed through the Events &amp; Presentations section of the Company\u2019s website at investors.ovidrx.com. An archived replay of the webcast will be available on the Company\u2019s website following the live presentation.<\/p>\n<p align=\"justify\">\n        <strong>About Ovid Therapeutics<\/strong>\n      <\/p>\n<p align=\"justify\">Ovid Therapeutics Inc. is a New York-based biopharmaceutical company striving to conquer seizures and intractable brain disorders with courageous science. The Company is advancing a focused pipeline of targeted small molecule candidates to modulate the intrinsic and extrinsic factors involved in neuronal hyperexcitation, which can cause seizures and other neuropathological symptoms. Programs Ovid seeks to develop include: GV101, a potent and highly selective ROCK2 inhibitor, for the potential treatment of lesions associated with cerebral cavernous malformations; OV329, a GABA-aminotransferase inhibitor, for the potential treatment of treatment-resistant seizures; and OV350, a direct activator of the KCC2 transporter, for the potential treatment of epilepsies. In addition, the Company&#8217;s ROCK2 inhibitor and KCC2 activator portfolios have the potential to treat other neurological conditions. Ovid also maintains a significant financial interest in the future regulatory development and potential commercialization of soticlestat, which Takeda is responsible for advancing globally. Soticlestat is a cholesterol 24-hydroxylase inhibitor, which is currently in Phase 3 trials for Dravet and Lennox-Gastaut syndromes. For more information about these and other Ovid research programs, please visit <a href=\"https:\/\/www.globenewswire.com\/Tracker?data=oRK1x9KuQyqspCLZuyvayws-_-RY6Pz4ktu5om6MQ7t-q8E4SUJbpu3AeeRGk-wOnpIKNrkSSI9Ob1bBPwRbmA==\" rel=\"nofollow noopener\" target=\"_blank\"><u>www.ovidrx.com<\/u><\/a>.<\/p>\n<p align=\"justify\">\n        <strong>Forward-Looking Statements<\/strong>\n      <\/p>\n<p align=\"justify\">This press release includes certain disclosures that contain \u201cforward-looking statements,\u201d including, without limitation: statements regarding the potential use of OV329, GV101 and OV350; the potential development of OV329, GV101 and the library of ROCK2 inhibitors and OV350 and other KCC2 compounds in Ovid\u2019s library; the potential therapeutic opportunity of OV329, GV101 and other ROCK2 inhibitors and OV350 and other KCC2 inhibitors; the potential opportunity for Soticlestat; and the timing of Takeda\u2019s two pivotal Phase 3 trials evaluating soticlestat for Dravet syndrome and Lennox-Gastaut syndrome. You can identify forward-looking statements because they contain words such as \u201canticipates,\u201d \u201cbelieves,\u201d \u201cexpected,\u201d \u201cintends,\u201d \u201cmay,\u201d \u201cplan,\u201d \u201cpotentially,\u201d \u201cseek,\u201d \u201cstrive,\u201d and \u201cwill,\u201d and similar expressions (as well as other words or expressions referencing future events, conditions or circumstances). Forward-looking statements are based on Ovid\u2019s current expectations and assumptions. Because forward-looking statements relate to the future, they are subject to inherent uncertainties, risks and changes in circumstances that may differ materially from those contemplated by the forward-looking statements, which are neither statements of historical fact nor guarantees or assurances of future performance. Important factors that could cause actual results to differ materially from those in the forward-looking statements include, without limitation, uncertainties inherent in the preclinical and clinical development and regulatory approval processes, risks related to Ovid\u2019s ability to achieve its financial objectives, the risk that Ovid may not be able to realize the intended benefits of its technology or its business strategy, or risks related to Ovid\u2019s ability to identify business development targets or strategic partners, to enter into strategic transactions on favorable terms, or to consummate and realize the benefits of any business development transactions. Additional risks that could cause actual results to differ materially from those in the forward-looking statements are set forth under the caption \u201cRisk Factors\u201d in Ovid\u2019s Quarterly Report on Form 10-Q filed with the Securities and Exchange Commission (\u201cSEC\u201d) on August 4, 2023, and in future filings Ovid makes with the SEC. Any forward-looking statements contained in this press release speak only as of the date hereof, and Ovid assumes no obligation to update any forward-looking statements contained herein, whether because of any new information, future events, changed circumstances or otherwise, except as otherwise required by law.<\/p>\n<p align=\"justify\">\n        <strong>Contacts<\/strong>\n      <\/p>\n<p align=\"justify\">\n        <strong>Investors and Media:<\/strong><br \/>\n        <br \/>Maeve Conneighton<br \/>Argot Partners (on behalf of Ovid)<br \/>212-596-7231<br \/>ovid@argotpartners.com<\/p>\n<p>      <img decoding=\"async\" class=\"__GNW8366DE3E__IMG\" src=\"https:\/\/www.globenewswire.com\/newsroom\/ti?nf=ODkxMzY1MiM1Nzg5NjkzIzIwNzAyNjA=\" \/><br \/>\n      <br \/>\n      <img decoding=\"async\" src=\"https:\/\/ml.globenewswire.com\/media\/NjY4OWY4OGQtZmUzOC00MTIyLTk4NmItMDRjZTI3ZmJhODhlLTEwODE4MzE=\/tiny\/Ovid-Therapeutics-Inc-.png\" \/>\n    <\/div>\n<div class=\"mw_contactinfo\"><\/div>\n","protected":false},"excerpt":{"rendered":"<p>NEW YORK, Aug. 30, 2023 (GLOBE NEWSWIRE) &#8212; Ovid Therapeutics Inc. (NASDAQ: OVID), a biopharmaceutical company committed to developing medicines that transform the lives of people with epilepsies and seizure-related disorders, today announced that management will participate in two upcoming investor conferences. Citi\u2019s 18 th Annual BioPharma Conference \u2013 Ovid will participate on Thursday, September 7, 2023 in Boston, Massachusetts. The H.C. Wainwright 25th Annual Global Investment Conference \u2013 Ovid\u2019s presentation will take place on Tuesday, September 12, 2023 at 10:30 a.m. ET in New York, New York. A live webcast of the H.C. Wainwright presentation can be accessed through the Events &amp; Presentations section of the Company\u2019s website at investors.ovidrx.com. An archived replay of the webcast will be available &hellip; <\/p>\n<p class=\"link-more\"><a href=\"https:\/\/www.marketnewsdesk.com\/index.php\/ovid-therapeutics-to-participate-in-upcoming-september-investor-conferences\/\" class=\"more-link\">Continue reading<span class=\"screen-reader-text\"> &#8220;Ovid Therapeutics to Participate in Upcoming September Investor Conferences&#8221;<\/span><\/a><\/p>\n","protected":false},"author":2,"featured_media":0,"comment_status":"closed","ping_status":"closed","sticky":false,"template":"","format":"standard","meta":{"footnotes":""},"categories":[],"tags":[],"class_list":["post-780944","post","type-post","status-publish","format-standard","hentry"],"yoast_head":"<!-- This site is optimized with the Yoast SEO plugin v27.5 - https:\/\/yoast.com\/product\/yoast-seo-wordpress\/ -->\n<title>Ovid Therapeutics to Participate in Upcoming September Investor Conferences - Market Newsdesk<\/title>\n<meta name=\"robots\" content=\"index, follow, max-snippet:-1, max-image-preview:large, max-video-preview:-1\" \/>\n<link rel=\"canonical\" href=\"https:\/\/www.marketnewsdesk.com\/index.php\/ovid-therapeutics-to-participate-in-upcoming-september-investor-conferences\/\" \/>\n<meta property=\"og:locale\" content=\"en_US\" \/>\n<meta property=\"og:type\" content=\"article\" \/>\n<meta property=\"og:title\" content=\"Ovid Therapeutics to Participate in Upcoming September Investor Conferences - Market Newsdesk\" \/>\n<meta property=\"og:description\" content=\"NEW YORK, Aug. 30, 2023 (GLOBE NEWSWIRE) &#8212; Ovid Therapeutics Inc. (NASDAQ: OVID), a biopharmaceutical company committed to developing medicines that transform the lives of people with epilepsies and seizure-related disorders, today announced that management will participate in two upcoming investor conferences. Citi\u2019s 18 th Annual BioPharma Conference \u2013 Ovid will participate on Thursday, September 7, 2023 in Boston, Massachusetts. The H.C. Wainwright 25th Annual Global Investment Conference \u2013 Ovid\u2019s presentation will take place on Tuesday, September 12, 2023 at 10:30 a.m. ET in New York, New York. A live webcast of the H.C. Wainwright presentation can be accessed through the Events &amp; Presentations section of the Company\u2019s website at investors.ovidrx.com. An archived replay of the webcast will be available &hellip; Continue reading &quot;Ovid Therapeutics to Participate in Upcoming September Investor Conferences&quot;\" \/>\n<meta property=\"og:url\" content=\"https:\/\/www.marketnewsdesk.com\/index.php\/ovid-therapeutics-to-participate-in-upcoming-september-investor-conferences\/\" \/>\n<meta property=\"og:site_name\" content=\"Market Newsdesk\" \/>\n<meta property=\"article:published_time\" content=\"2023-08-30T13:34:29+00:00\" \/>\n<meta property=\"og:image\" content=\"https:\/\/www.globenewswire.com\/newsroom\/ti?nf=ODkxMzY1MiM1Nzg5NjkzIzIwNzAyNjA=\" \/>\n<meta name=\"author\" content=\"Newsdesk\" \/>\n<meta name=\"twitter:card\" content=\"summary_large_image\" \/>\n<meta name=\"twitter:label1\" content=\"Written by\" \/>\n\t<meta name=\"twitter:data1\" content=\"Newsdesk\" \/>\n\t<meta name=\"twitter:label2\" content=\"Est. reading time\" \/>\n\t<meta name=\"twitter:data2\" content=\"3 minutes\" \/>\n<script type=\"application\/ld+json\" class=\"yoast-schema-graph\">{\"@context\":\"https:\\\/\\\/schema.org\",\"@graph\":[{\"@type\":\"Article\",\"@id\":\"https:\\\/\\\/www.marketnewsdesk.com\\\/index.php\\\/ovid-therapeutics-to-participate-in-upcoming-september-investor-conferences\\\/#article\",\"isPartOf\":{\"@id\":\"https:\\\/\\\/www.marketnewsdesk.com\\\/index.php\\\/ovid-therapeutics-to-participate-in-upcoming-september-investor-conferences\\\/\"},\"author\":{\"name\":\"Newsdesk\",\"@id\":\"https:\\\/\\\/www.marketnewsdesk.com\\\/#\\\/schema\\\/person\\\/482f27a394d4fda80ecb5499e519d979\"},\"headline\":\"Ovid Therapeutics to Participate in Upcoming September Investor Conferences\",\"datePublished\":\"2023-08-30T13:34:29+00:00\",\"mainEntityOfPage\":{\"@id\":\"https:\\\/\\\/www.marketnewsdesk.com\\\/index.php\\\/ovid-therapeutics-to-participate-in-upcoming-september-investor-conferences\\\/\"},\"wordCount\":703,\"image\":{\"@id\":\"https:\\\/\\\/www.marketnewsdesk.com\\\/index.php\\\/ovid-therapeutics-to-participate-in-upcoming-september-investor-conferences\\\/#primaryimage\"},\"thumbnailUrl\":\"https:\\\/\\\/www.globenewswire.com\\\/newsroom\\\/ti?nf=ODkxMzY1MiM1Nzg5NjkzIzIwNzAyNjA=\",\"inLanguage\":\"en-US\"},{\"@type\":\"WebPage\",\"@id\":\"https:\\\/\\\/www.marketnewsdesk.com\\\/index.php\\\/ovid-therapeutics-to-participate-in-upcoming-september-investor-conferences\\\/\",\"url\":\"https:\\\/\\\/www.marketnewsdesk.com\\\/index.php\\\/ovid-therapeutics-to-participate-in-upcoming-september-investor-conferences\\\/\",\"name\":\"Ovid Therapeutics to Participate in Upcoming September Investor Conferences - Market Newsdesk\",\"isPartOf\":{\"@id\":\"https:\\\/\\\/www.marketnewsdesk.com\\\/#website\"},\"primaryImageOfPage\":{\"@id\":\"https:\\\/\\\/www.marketnewsdesk.com\\\/index.php\\\/ovid-therapeutics-to-participate-in-upcoming-september-investor-conferences\\\/#primaryimage\"},\"image\":{\"@id\":\"https:\\\/\\\/www.marketnewsdesk.com\\\/index.php\\\/ovid-therapeutics-to-participate-in-upcoming-september-investor-conferences\\\/#primaryimage\"},\"thumbnailUrl\":\"https:\\\/\\\/www.globenewswire.com\\\/newsroom\\\/ti?nf=ODkxMzY1MiM1Nzg5NjkzIzIwNzAyNjA=\",\"datePublished\":\"2023-08-30T13:34:29+00:00\",\"author\":{\"@id\":\"https:\\\/\\\/www.marketnewsdesk.com\\\/#\\\/schema\\\/person\\\/482f27a394d4fda80ecb5499e519d979\"},\"breadcrumb\":{\"@id\":\"https:\\\/\\\/www.marketnewsdesk.com\\\/index.php\\\/ovid-therapeutics-to-participate-in-upcoming-september-investor-conferences\\\/#breadcrumb\"},\"inLanguage\":\"en-US\",\"potentialAction\":[{\"@type\":\"ReadAction\",\"target\":[\"https:\\\/\\\/www.marketnewsdesk.com\\\/index.php\\\/ovid-therapeutics-to-participate-in-upcoming-september-investor-conferences\\\/\"]}]},{\"@type\":\"ImageObject\",\"inLanguage\":\"en-US\",\"@id\":\"https:\\\/\\\/www.marketnewsdesk.com\\\/index.php\\\/ovid-therapeutics-to-participate-in-upcoming-september-investor-conferences\\\/#primaryimage\",\"url\":\"https:\\\/\\\/www.globenewswire.com\\\/newsroom\\\/ti?nf=ODkxMzY1MiM1Nzg5NjkzIzIwNzAyNjA=\",\"contentUrl\":\"https:\\\/\\\/www.globenewswire.com\\\/newsroom\\\/ti?nf=ODkxMzY1MiM1Nzg5NjkzIzIwNzAyNjA=\"},{\"@type\":\"BreadcrumbList\",\"@id\":\"https:\\\/\\\/www.marketnewsdesk.com\\\/index.php\\\/ovid-therapeutics-to-participate-in-upcoming-september-investor-conferences\\\/#breadcrumb\",\"itemListElement\":[{\"@type\":\"ListItem\",\"position\":1,\"name\":\"Home\",\"item\":\"https:\\\/\\\/www.marketnewsdesk.com\\\/\"},{\"@type\":\"ListItem\",\"position\":2,\"name\":\"Ovid Therapeutics to Participate in Upcoming September Investor Conferences\"}]},{\"@type\":\"WebSite\",\"@id\":\"https:\\\/\\\/www.marketnewsdesk.com\\\/#website\",\"url\":\"https:\\\/\\\/www.marketnewsdesk.com\\\/\",\"name\":\"Market Newsdesk\",\"description\":\"Latest Business News in Real Time\",\"potentialAction\":[{\"@type\":\"SearchAction\",\"target\":{\"@type\":\"EntryPoint\",\"urlTemplate\":\"https:\\\/\\\/www.marketnewsdesk.com\\\/?s={search_term_string}\"},\"query-input\":{\"@type\":\"PropertyValueSpecification\",\"valueRequired\":true,\"valueName\":\"search_term_string\"}}],\"inLanguage\":\"en-US\"},{\"@type\":\"Person\",\"@id\":\"https:\\\/\\\/www.marketnewsdesk.com\\\/#\\\/schema\\\/person\\\/482f27a394d4fda80ecb5499e519d979\",\"name\":\"Newsdesk\",\"image\":{\"@type\":\"ImageObject\",\"inLanguage\":\"en-US\",\"@id\":\"https:\\\/\\\/secure.gravatar.com\\\/avatar\\\/a0d0bd5b0f0ca12a265a459b13169dac35f33776d8501eda5e68844a366f2f46?s=96&d=mm&r=g\",\"url\":\"https:\\\/\\\/secure.gravatar.com\\\/avatar\\\/a0d0bd5b0f0ca12a265a459b13169dac35f33776d8501eda5e68844a366f2f46?s=96&d=mm&r=g\",\"contentUrl\":\"https:\\\/\\\/secure.gravatar.com\\\/avatar\\\/a0d0bd5b0f0ca12a265a459b13169dac35f33776d8501eda5e68844a366f2f46?s=96&d=mm&r=g\",\"caption\":\"Newsdesk\"},\"url\":\"https:\\\/\\\/www.marketnewsdesk.com\\\/index.php\\\/author\\\/newsdesk\\\/\"}]}<\/script>\n<!-- \/ Yoast SEO plugin. -->","yoast_head_json":{"title":"Ovid Therapeutics to Participate in Upcoming September Investor Conferences - Market Newsdesk","robots":{"index":"index","follow":"follow","max-snippet":"max-snippet:-1","max-image-preview":"max-image-preview:large","max-video-preview":"max-video-preview:-1"},"canonical":"https:\/\/www.marketnewsdesk.com\/index.php\/ovid-therapeutics-to-participate-in-upcoming-september-investor-conferences\/","og_locale":"en_US","og_type":"article","og_title":"Ovid Therapeutics to Participate in Upcoming September Investor Conferences - Market Newsdesk","og_description":"NEW YORK, Aug. 30, 2023 (GLOBE NEWSWIRE) &#8212; Ovid Therapeutics Inc. (NASDAQ: OVID), a biopharmaceutical company committed to developing medicines that transform the lives of people with epilepsies and seizure-related disorders, today announced that management will participate in two upcoming investor conferences. Citi\u2019s 18 th Annual BioPharma Conference \u2013 Ovid will participate on Thursday, September 7, 2023 in Boston, Massachusetts. The H.C. Wainwright 25th Annual Global Investment Conference \u2013 Ovid\u2019s presentation will take place on Tuesday, September 12, 2023 at 10:30 a.m. ET in New York, New York. A live webcast of the H.C. Wainwright presentation can be accessed through the Events &amp; Presentations section of the Company\u2019s website at investors.ovidrx.com. An archived replay of the webcast will be available &hellip; Continue reading \"Ovid Therapeutics to Participate in Upcoming September Investor Conferences\"","og_url":"https:\/\/www.marketnewsdesk.com\/index.php\/ovid-therapeutics-to-participate-in-upcoming-september-investor-conferences\/","og_site_name":"Market Newsdesk","article_published_time":"2023-08-30T13:34:29+00:00","og_image":[{"url":"https:\/\/www.globenewswire.com\/newsroom\/ti?nf=ODkxMzY1MiM1Nzg5NjkzIzIwNzAyNjA=","type":"","width":"","height":""}],"author":"Newsdesk","twitter_card":"summary_large_image","twitter_misc":{"Written by":"Newsdesk","Est. reading time":"3 minutes"},"schema":{"@context":"https:\/\/schema.org","@graph":[{"@type":"Article","@id":"https:\/\/www.marketnewsdesk.com\/index.php\/ovid-therapeutics-to-participate-in-upcoming-september-investor-conferences\/#article","isPartOf":{"@id":"https:\/\/www.marketnewsdesk.com\/index.php\/ovid-therapeutics-to-participate-in-upcoming-september-investor-conferences\/"},"author":{"name":"Newsdesk","@id":"https:\/\/www.marketnewsdesk.com\/#\/schema\/person\/482f27a394d4fda80ecb5499e519d979"},"headline":"Ovid Therapeutics to Participate in Upcoming September Investor Conferences","datePublished":"2023-08-30T13:34:29+00:00","mainEntityOfPage":{"@id":"https:\/\/www.marketnewsdesk.com\/index.php\/ovid-therapeutics-to-participate-in-upcoming-september-investor-conferences\/"},"wordCount":703,"image":{"@id":"https:\/\/www.marketnewsdesk.com\/index.php\/ovid-therapeutics-to-participate-in-upcoming-september-investor-conferences\/#primaryimage"},"thumbnailUrl":"https:\/\/www.globenewswire.com\/newsroom\/ti?nf=ODkxMzY1MiM1Nzg5NjkzIzIwNzAyNjA=","inLanguage":"en-US"},{"@type":"WebPage","@id":"https:\/\/www.marketnewsdesk.com\/index.php\/ovid-therapeutics-to-participate-in-upcoming-september-investor-conferences\/","url":"https:\/\/www.marketnewsdesk.com\/index.php\/ovid-therapeutics-to-participate-in-upcoming-september-investor-conferences\/","name":"Ovid Therapeutics to Participate in Upcoming September Investor Conferences - Market Newsdesk","isPartOf":{"@id":"https:\/\/www.marketnewsdesk.com\/#website"},"primaryImageOfPage":{"@id":"https:\/\/www.marketnewsdesk.com\/index.php\/ovid-therapeutics-to-participate-in-upcoming-september-investor-conferences\/#primaryimage"},"image":{"@id":"https:\/\/www.marketnewsdesk.com\/index.php\/ovid-therapeutics-to-participate-in-upcoming-september-investor-conferences\/#primaryimage"},"thumbnailUrl":"https:\/\/www.globenewswire.com\/newsroom\/ti?nf=ODkxMzY1MiM1Nzg5NjkzIzIwNzAyNjA=","datePublished":"2023-08-30T13:34:29+00:00","author":{"@id":"https:\/\/www.marketnewsdesk.com\/#\/schema\/person\/482f27a394d4fda80ecb5499e519d979"},"breadcrumb":{"@id":"https:\/\/www.marketnewsdesk.com\/index.php\/ovid-therapeutics-to-participate-in-upcoming-september-investor-conferences\/#breadcrumb"},"inLanguage":"en-US","potentialAction":[{"@type":"ReadAction","target":["https:\/\/www.marketnewsdesk.com\/index.php\/ovid-therapeutics-to-participate-in-upcoming-september-investor-conferences\/"]}]},{"@type":"ImageObject","inLanguage":"en-US","@id":"https:\/\/www.marketnewsdesk.com\/index.php\/ovid-therapeutics-to-participate-in-upcoming-september-investor-conferences\/#primaryimage","url":"https:\/\/www.globenewswire.com\/newsroom\/ti?nf=ODkxMzY1MiM1Nzg5NjkzIzIwNzAyNjA=","contentUrl":"https:\/\/www.globenewswire.com\/newsroom\/ti?nf=ODkxMzY1MiM1Nzg5NjkzIzIwNzAyNjA="},{"@type":"BreadcrumbList","@id":"https:\/\/www.marketnewsdesk.com\/index.php\/ovid-therapeutics-to-participate-in-upcoming-september-investor-conferences\/#breadcrumb","itemListElement":[{"@type":"ListItem","position":1,"name":"Home","item":"https:\/\/www.marketnewsdesk.com\/"},{"@type":"ListItem","position":2,"name":"Ovid Therapeutics to Participate in Upcoming September Investor Conferences"}]},{"@type":"WebSite","@id":"https:\/\/www.marketnewsdesk.com\/#website","url":"https:\/\/www.marketnewsdesk.com\/","name":"Market Newsdesk","description":"Latest Business News in Real Time","potentialAction":[{"@type":"SearchAction","target":{"@type":"EntryPoint","urlTemplate":"https:\/\/www.marketnewsdesk.com\/?s={search_term_string}"},"query-input":{"@type":"PropertyValueSpecification","valueRequired":true,"valueName":"search_term_string"}}],"inLanguage":"en-US"},{"@type":"Person","@id":"https:\/\/www.marketnewsdesk.com\/#\/schema\/person\/482f27a394d4fda80ecb5499e519d979","name":"Newsdesk","image":{"@type":"ImageObject","inLanguage":"en-US","@id":"https:\/\/secure.gravatar.com\/avatar\/a0d0bd5b0f0ca12a265a459b13169dac35f33776d8501eda5e68844a366f2f46?s=96&d=mm&r=g","url":"https:\/\/secure.gravatar.com\/avatar\/a0d0bd5b0f0ca12a265a459b13169dac35f33776d8501eda5e68844a366f2f46?s=96&d=mm&r=g","contentUrl":"https:\/\/secure.gravatar.com\/avatar\/a0d0bd5b0f0ca12a265a459b13169dac35f33776d8501eda5e68844a366f2f46?s=96&d=mm&r=g","caption":"Newsdesk"},"url":"https:\/\/www.marketnewsdesk.com\/index.php\/author\/newsdesk\/"}]}},"_links":{"self":[{"href":"https:\/\/www.marketnewsdesk.com\/index.php\/wp-json\/wp\/v2\/posts\/780944","targetHints":{"allow":["GET"]}}],"collection":[{"href":"https:\/\/www.marketnewsdesk.com\/index.php\/wp-json\/wp\/v2\/posts"}],"about":[{"href":"https:\/\/www.marketnewsdesk.com\/index.php\/wp-json\/wp\/v2\/types\/post"}],"author":[{"embeddable":true,"href":"https:\/\/www.marketnewsdesk.com\/index.php\/wp-json\/wp\/v2\/users\/2"}],"replies":[{"embeddable":true,"href":"https:\/\/www.marketnewsdesk.com\/index.php\/wp-json\/wp\/v2\/comments?post=780944"}],"version-history":[{"count":0,"href":"https:\/\/www.marketnewsdesk.com\/index.php\/wp-json\/wp\/v2\/posts\/780944\/revisions"}],"wp:attachment":[{"href":"https:\/\/www.marketnewsdesk.com\/index.php\/wp-json\/wp\/v2\/media?parent=780944"}],"wp:term":[{"taxonomy":"category","embeddable":true,"href":"https:\/\/www.marketnewsdesk.com\/index.php\/wp-json\/wp\/v2\/categories?post=780944"},{"taxonomy":"post_tag","embeddable":true,"href":"https:\/\/www.marketnewsdesk.com\/index.php\/wp-json\/wp\/v2\/tags?post=780944"}],"curies":[{"name":"wp","href":"https:\/\/api.w.org\/{rel}","templated":true}]}}